TARGET-CTCA Trial

Start date:
August 2019

End date:
August 2024

Co-ordinated by:
EMERGE and the Cardiology Research Team

Main trial site:
NHS Lothian and NHS Greater Glasgow and Clyde

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants.

This is a randomised control trial funded by the British Heart Foundation, aiming to evaluate troponin in acute chest pain to risk stratify and guide effective use of computed tomography coronary angiography (CTCA).

Inclusion Criteria:

• Presenting to hospital with symptoms of suspected ACS
• Age 18 or over
• Maximum high-sensitivity cardiac troponin concentration between 5ng/L and the 99th percentile

Exclusion Criteria:

• Diagnosis of myocardial infarction during index presentation
• Clear alternative diagnosis or participant requires further inpatient clinical assessment
• Recent CTCA or invasive coronary angiogram (within 1 year)
• Patient inability to undergo CT scanning, e.g. due to severe renal failure (estimated glomerular filtration rate <30 mL/min) or major allergy to iodinated contrast media
• Current pregnancy or breast feeding
• Inability to give informed consent
• Further investigation for coronary artery disease would not be in the patient’s interest, e.g. due to limited life expectancy, quality of life or functional status
• Previous randomisation into the trial